In addition to adapting Abbott’s HCV core antigen assay to the RDT platform used for our infant HIV p24 antigen test, we will explore two alternatives with the goal of improving performance and reducing cost. First, the limit of detection could likely be improved by using a luminescent label instead of our carbon nanoparticles. A reader for this approach would not be significantly more expensive than the one we plan to use with our carbon label. Second, an acid shock method of disrupting the immune complex, which Abbott uses in their Architect assay. This would reduce costs and possibly shorten turnaround times.
|Effective start/end date||6/30/15 → 9/30/16|
- Northwestern Global Health Foundation (Letter 6/30/15)
- Foundation for Innovative New Diagnostics (Letter 6/30/15)